<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082562</url>
  </required_header>
  <id_info>
    <org_study_id>CV198-002</org_study_id>
    <secondary_id>2009-012032-32</secondary_id>
    <nct_id>NCT01082562</nct_id>
  </id_info>
  <brief_title>Safety Study of BMS-844421 for Treatment of Hypercholesterolemia</brief_title>
  <official_title>Randomized, Double-blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study to Evaluate the Safety , Pharmacokinetics and Pharmacodynamics of BMS-844421 in Healthy Subjects and in Subjects With Elevated Cholesterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, serum concentrations and
      pharmacodynamic effects on serum low-density lipoprotein (LDL) cholesterol of single and
      multiple subcutaneous and intravenous doses of BMS-844421 in healthy subjects (SAD) and in
      subjects with elevated cholesterol (MAD).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To asses safety, tolerability, pharmacodynamic effects of BMS-844421 on PCSK9 concentrations</measure>
    <time_frame>At the conclusion of the MAD part of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess single and multiple dose pharmacokinetics of BMS-844421</measure>
    <time_frame>All outcomes will be assessed at the conclusion of the MAD part of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the absolute bioavailability of single BMS-844421 SC doses</measure>
    <time_frame>All outcomes will be assessed at the conclusion of the MAD part of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effects of multiple doses of BMS-844421on lipid components</measure>
    <time_frame>All outcomes will be assessed at the conclusion of the MAD part of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Arm 1 - BMS-844421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - BMS-844421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 - BMS-844421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7 - BMS-844421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9 - BMS-844421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 10 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 11 - BMS-844421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 12 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 13 - BMS-844421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 14 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 15 - BMS-844421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 16 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-844421</intervention_name>
    <description>Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg
SAD: Once, 1 Day
MAD: IV loading followed by 4 weekly doses, 29 Days</description>
    <arm_group_label>Arm 1 - BMS-844421</arm_group_label>
    <arm_group_label>Arm 3 - BMS-844421</arm_group_label>
    <arm_group_label>Arm 5 - BMS-844421</arm_group_label>
    <arm_group_label>Arm 7 - BMS-844421</arm_group_label>
    <arm_group_label>Arm 9 - BMS-844421</arm_group_label>
    <arm_group_label>Arm 11 - BMS-844421</arm_group_label>
    <arm_group_label>Arm 13 - BMS-844421</arm_group_label>
    <arm_group_label>Arm 15 - BMS-844421</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride injection solution</intervention_name>
    <description>Injection solution, Subcutaneous, 37.5 mg
SAD: Once, 1 Day
MAD: IV loading followed by 4 weekly doses, 29 Days</description>
    <arm_group_label>Arm 2 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_label>Arm 4 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_label>Arm 6 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_label>Arm 8 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_label>Arm 10 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_label>Arm 12 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_label>Arm 14 - 0.9% sodium chloride injection solution</arm_group_label>
    <arm_group_label>Arm 16 - 0.9% sodium chloride injection solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Subjects (SAD)

          -  Healthy Subjects (MAD) with untreated elevated cholesterol

          -  Body Mass Index (BMI) of 18 to 30 kg/mÂ² inclusive

          -  Women who are not of childbearing potential and men, ages 18 to 45

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of liver or renal disorders

          -  Prior use of any prescription or over-the-counter lipid lowering drugs, within 8 weeks
             prior to study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>January 25, 2011</last_update_submitted>
  <last_update_submitted_qc>January 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

